Geron to Present at Upcoming Investor Conferences in April

Rhea-AI Summary

Geron Corporation (Nasdaq: GERN), a biopharmaceutical company focused on hematologic malignancies, announced that John A. Scarlett, M.D., the Chairman and CEO, will participate in fireside chats at two upcoming investor conferences.

• 22nd Annual Needham Virtual Healthcare Conference
  Date: April 20, 2023
  Time: 10:15 a.m. ET
• Stifel 2023 Virtual Targeted Oncology Days
  Date: April 25, 2023
  Time: 2:00 p.m. ET

Webcasts of the chats will be accessible via the Investor Relations section of Geron’s website and archived for 30 days post-event. Geron is advancing its first-in-class telomerase inhibitor, imetelstat, which aims to impact the treatment of these diseases significantly.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in fireside chats at following investor conferences:

• 22^nd Annual Needham Virtual Healthcare Conference
  Thursday, April 20 at 10:15 a.m. ET

• Stifel 2023 Virtual Targeted Oncology Days
  Tuesday, April 25 at 2:00 p.m. ET

A webcast of each fireside chat and corporate presentation will be available through the Investor Relations section of Geron’s website under Events. Following each scheduled conference event, the related webcast will be archived and available for replay for a period of 30 days.

About Geron

Geron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Its investigational first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize winning science in a treatment that may alter the underlying course of these diseases. To learn more, visit http://www.geron.com/or follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230412005663/en/

Aron Feingold

Investor and Media Relations

investor@geron.com

media@geron.com

Source: Geron Corporation

FAQ

When is John A. Scarlett participating in the Needham Virtual Healthcare Conference?

John A. Scarlett will participate in the Needham Virtual Healthcare Conference on April 20, 2023, at 10:15 a.m. ET.

What date is the Stifel 2023 Virtual Targeted Oncology Days event?

The Stifel 2023 Virtual Targeted Oncology Days will take place on April 25, 2023, at 2:00 p.m. ET.

Where can I watch the webcasts of Geron's investor conference presentations?

Webcasts of Geron's investor conference presentations will be available in the Investor Relations section of Geron’s website and will be archived for 30 days after each event.

What is imetelstat, being developed by Geron Corporation?

Imetelstat is a first-in-class telomerase inhibitor being developed by Geron Corporation, aimed at treating hematologic malignancies.